Achieve’s cytisinicline CRL cited a prior facility and incomplete labeling, not clinical failure. Why this CMC rejection ...
Bright biotech illustration for Unicycive’s OLC CRL, showing nanoparticle formulation, manufacturing control strategy, FDA quality risk and CDMO execution failure. The FDA did not reject Oxylanthanum ...
Viridian’s Lumvoa approval breaks Tepezza’s TED monopoly. Inside the label, Phase 3 data, safety risks, payer hurdles and ...
AlzeCure did not prove ACD856 works in Alzheimer’s patients. It proved something else: early clinical safety, brain exposure, and a novel CNS mechanism can still be valuable enough to move a small ...
FDA Issues CRL to Sobi for NASP in Uncontrolled Gout, but the letter did not attack the clinical case. It attacked ...
SigHT is formally a long-term observational study. Strategically, its timing points to something larger: Tanabe is building a ...
Phase 3 Data, Capital Structure and the Cost of Independence Revolution Medicines has not eliminated acquisition interest. It has eliminated the financial urgency that could force it to accept an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results